Edgewise Therapeutics Inc.

8.53+0.2600+3.14%Vol 934.23K1Y Perf -66.91%
Jun 24th, 2022 16:00 DELAYED
BID5.13 ASK10.20
Open8.31 Previous Close8.27
Pre-Market- After-Market8.53
 - -  - -%
Target Price
25.00 
Analyst Rating
Moderate Buy 1.60
Potential %
193.08 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.45 
Earnings Rating
Market Cap422.87M 
Earnings Date
8th Aug 2022
Alpha-0.11 Standard Deviation0.10
Beta-0.10 

Today's Price Range

7.818.56

52W Range

5.4127.03

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
28.66%
1 Month
50.44%
3 Months
-8.08%
6 Months
-46.79%
1 Year
-66.91%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EWTX8.530.26003.14
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.29-0.30-3.45
Q04 2021-0.28-0.267.14
Q03 2021-0.22-0.26-18.18
Q02 2021-0.18-0.21-16.67
Q01 2021-0.16-0.1412.50
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date8th Aug 2022
Estimated EPS Next Report-0.34
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume934.23K
Shares Outstanding49.58K
Shares Float29.48M
Trades Count5.25K
Dollar Volume7.87M
Avg. Volume241.98K
Avg. Weekly Volume297.25K
Avg. Monthly Volume208.27K
Avg. Quarterly Volume220.44K

Edgewise Therapeutics Inc. (NASDAQ: EWTX) stock closed at 8.53 per share at the end of the most recent trading day (a 3.14% change compared to the prior day closing price) with a volume of 934.23K shares and market capitalization of 422.87M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. Edgewise Therapeutics Inc. CEO is Kevin Koch.

The one-year performance of Edgewise Therapeutics Inc. stock is -66.91%, while year-to-date (YTD) performance is -44.18%. EWTX stock has a five-year performance of %. Its 52-week range is between 5.405 and 27.025, which gives EWTX stock a 52-week price range ratio of 14.45%

Edgewise Therapeutics Inc. currently has a PE ratio of -6.60, a price-to-book (PB) ratio of 1.26, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -17.35%, a ROC of -17.92% and a ROE of -17.88%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Edgewise Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Edgewise Therapeutics Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Edgewise Therapeutics Inc. is Moderate Buy (1.6), with a target price of $25, which is +193.08% compared to the current price. The earnings rating for Edgewise Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edgewise Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edgewise Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.39, ATR14 : 0.58, CCI20 : 213.34, Chaikin Money Flow : 0.50, MACD : 0.17, Money Flow Index : 90.94, ROC : 27.50, RSI : 69.11, STOCH (14,3) : 98.99, STOCH RSI : 1.00, UO : 75.02, Williams %R : -1.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edgewise Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
3 (60.00 %)
3 (75.00 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.60
Moderate Buy
1.60
Strong Buy
1.50

Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

CEO: Kevin Koch

Telephone: +1 303 735-8373

Address: 3415 Colorado Avenue, Boulder 80303, CO, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

Bearish Bullish

60%40%

TipRanks News for EWTX

Tue, 24 May 2022 16:42 GMT Edgewise Therapeutics (EWTX) Gets a Hold Rating from Goldman Sachs

- TipRanks. All rights reserved.

Thu, 12 May 2022 12:37 GMT Edgewise Therapeutics (EWTX) Gets a Buy Rating from SVB Securities

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 14:11 GMT Edgewise Therapeutics (EWTX) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits